

Redacted



Criteria	Yes	No
Diagnosis Discrepancy		✓
Primary Tumor Site Discrepancy		✓
HIPAA Discrepancy		✓
Prior Malignancy History		✓
Dual/Synchronous Primary Noted		✓
Case is (circle):	QUALIFIED /	DISQUALIFIED
Reviewer Initials	RB	Date Reviewed: 2/12/12

**Surgical Pathology Report****Final**

**SURGICAL PATHOLOGY REPORT**  
**FINAL WITH ADDENDUM**

Patient Name:

Address:

Service:

Accession #:

Taken:

Gender:

F

MRN :

Received:

DOB:

Hospital #: Patient Type:

Accessioned:

Reported:

Physician(s):

**DIAGNOSIS:**

- A. RIGHT EXTERNAL ILIAC LYMPH NODES, EXCISION
  - TWO LYMPH NODES, NEGATIVE FOR TUMOR (0/2)
- B. RIGHT OBTURATOR LYMPH NODES, EXCISION
  - TWO LYMPH NODES, NEGATIVE FOR TUMOR (0/2)
- C. LEFT EXTERNAL ILIAC LYMPH NODES, EXCISION
  - THREE LYMPH NODES, NEGATIVE FOR TUMOR (0/3)
- D. LEFT OBTURATOR LYMPH NODES, EXCISION
  - THREE LYMPH NODES, NEGATIVE FOR TUMOR (0/3)
- E. UTERUS, CERVIX WITH BILATERAL TUBES AND OVARIES, TOTAL ABDOMINAL HYSTERECTOMY WITH BILATERAL SALPINGO-OOPHORECTOMY:

ICD-0-3

adenocarcinoma,  
endocervical type

8384/3

Site: cervix, NOS

2/28/12  
CD  
C53.9**CERVIX:**

- INVASIVE POORLY-DIFFERENTIATED ADENOCARCINOMA OF THE ENDOCERVIX
- THE MAXIMUM LATERAL EXTENSION OF THE TUMOR IS 3.3 CM
- TUMOR INVades TO A DEPTH OF 0.6 CM WERE THE MAXIMUM CERVICAL THICKNESS IS 1.1 CM (THE TUMOR IS LARGELY EXOPHYtic)
- NO LYMPHOVASCULAR SPACE INVASION IS IDENTIFIED
- TUMOR DOES NOT INVOLVE THE ECTOCERVIX OR THE VAGINA
- BILATERAL PARAMETRIAL FREE OF TUMOR

**VAGINA:**

- NEGATIVE FOR TUMOR

**UTERINE BODY:**

- PROLIFERATIVE ENDOMETRIUM
- HISTOLOGICALLY UNREMARKABLE MYOMETRIUM
- NEGATIVE FOR TUMOR

**BILATERAL FALLOPIAN TUBES AND OVARIES:**

- NEGATIVE FOR TUMOR

Patient Name: [REDACTED]  
DOB: [REDACTED]

## Surgical Pathology Report

Final

### SURGICAL PATHOLOGY REPORT

By this signature, I attest that the above diagnosis is based upon my personal examination of the slides (and/or other material indicated in the diagnosis).

\*\*\*Report Electronically Reviewed \_\_\_\_\_ by [REDACTED]

#### Intraoperative Consultation:

Intraoperative non-microscopic consultation was obtained and interpreted as: "Called to pick up 'hysterectomy and bilateral salpingo-oophorectomy specimen with vaginal cuff.' The specimen weighs 130.8 gm. The cervix measures 4.2 x 3.5 cm and has a fungating mass from 8 to 12 o'clock position (right sided). It measures 2.9 x 1.8 x 1.1 cm, and is 0.6 cm from the vaginal cuff margin. It superficially invades the cervix, approaching the serosal margin to approximately 1.1 cm. The uterus measures 8 x 4.5 x 4 cm with attached vaginal cuff that measures 0.7 cm (right sided) 1.4 cm (left sided) 1.7 cm (posterior), and 1.4 cm (anterior). A portion of tumor and normal tissue are submitted for tissue bank. Right serosal margin is inked black, left serosal margin is inked blue," by [REDACTED]

#### Microscopic Description and Comment:

Microscopic examination substantiates the above cited diagnosis.

#### History:

The patient is a [REDACTED] year old woman with cervical carcinoma. Operative procedure: Radical hysterectomy and lymph node dissection.

#### Specimen(s) Received:

- A: LYMPH NODES, RIGHT EXTERNAL ILIAC
- B: LYMPH NODE, RIGHT OBTURATOR
- C: LYMPH NODE, LEFT EXTERNAL ILIAC
- D: LYMPH NODE, LEFT OBTURATOR
- E: HYSTERECTOMY, RADICAL WITH UPPER VAGINA

#### Gross Description:

The specimens are received in five formalin-filled containers, each labeled [REDACTED]. The first container is labeled "right external iliac lymph node" and it holds multiple pieces of fibrofatty tissue measuring, in aggregate, 6 x 3.5 x 1.8 cm, from which two enlarged lymph nodes are dissected measuring 2 and 2.7 cm in maximum dimension. Labeled A1 and A2 - single node bisected and put in two cassettes; A3 - single node bisected and submitted in a single cassette, Jar 1.

The second container is labeled "right obturator lymph nodes" and it holds multiple pieces of fibrofatty tissue measuring, in aggregate, 4.5 x 3.5 x 2.5 cm, from which two lymph nodes are dissected, varying from 1 cm to 3.4 cm in maximum dimension. Labeled B1 and B2 - single node bisected and submitted in two cassettes; B3 - single bisected node. Jar 1.

The third container is labeled "left external iliac lymph node." It holds multiple pieces of fibrofatty tissue measuring, in aggregate, 6.5 x 6 x 2 cm, from which three lymph nodes, varying in size from 0.7 to 3 cm in maximum dimension are bisected. Labeled C1 and C2 - single node bisected and submitted in two cassettes; C3 - two bisected nodes. Jar 1.

The fourth container is labeled "left obturator lymph nodes" and it holds multiple pieces of fibrofatty tissue measuring,

Patient Name: [REDACTED]  
DOB: [REDACTED]

## Surgical Pathology Report

Final

### SURGICAL PATHOLOGY REPORT

In aggregate, 5.5 x 2.5 x 2 cm, from which three lymph nodes varying from 0.5 to 2.2 cm in maximum dimension are dissected. Labeled D1 and D2 - single node bisected and submitted in two cassettes; D3 to D5 - single node trisected and submitted in three cassettes; D6 - single small node entirely submitted. Jar 1.

The fifth container is labeled "radical hysterectomy with upper vagina." It holds an already opened and pinned specimen of uterus, cervix with bilateral tubes and ovaries and the upper portion of vagina. The specimen weighs 123 gm. The attached cervix measures 3.5 x 3.5 x 3 cm, the vaginal cuff measures 0.7 cm on the right, 1.4 cm on the left, and 1.7 cm posteriorly, and 1.4 cm anteriorly. The right parametrial soft tissue measures 1.5 x 1 x 1 cm and the left measures 1.5 x 1 x 1 cm. The 3 cm in length x 5 cm in diameter ectocervix is distorted by a 3.3 x 2.5 x 1.3 cm firm, white, centrally ulcerated, fungating tumor mass involving bone the anterior and the posterior cervical lips on the right side and invading to a maximum depth of 1.4 cm where the total cervical thickness is 2.1 cm. The tumor lies 0.6 cm from the nearest vaginal cuff margin (right anterior). The vaginal cuff is smooth, shiny, tan and grossly free of tumor. Endocervical canal measures 1.5 cm in length, is gray-tan and is free of tumor. The 4 x 1.5 cm endometrial cavity is lined by unremarkable gray-tan endometrium which is 0.1 cm in thickness. The myometrium is uniform with an average thickness of 2 cm. The parametrial soft tissue appears grossly unremarkable. The serosal surface is smooth and shiny without adhesions. The 2.8 x 1.5 x 0.8 cm right ovary has a convoluted surface and on sectioning shows multiple hemorrhagic cysts. The right fallopian tube measures 6.3 x 0.7 cm, and shows multiple Walthard's rests, and on sectioning shows an unremarkable pinpoint lumen. A 3.5 x 2 x 1 cm left ovary shows a convoluted outer surface and on sectioning, shows a single hemorrhagic cyst that measures 2 cm in maximum dimension. The left tube measures 5.5 x 0.7 cm and shows a single paratubal cyst measuring 1.3 cm in maximum dimension. On sectioning, it shows an unremarkable pinpoint lumen. Labeled E1 and E2 - anterior vaginal cuff shave margin; E3 and E4 - posterior vaginal cuff shave margin; E5 to E8 - anterior cervical tumor; E9 to A12 - posterior cervical tumor; E13 - right parametrial soft tissue; E14 - left parametrial soft tissue; E15 - anterior endocervix; E16 - posterior endocervix; E17 - anterior endomyometrium; E18 - posterior endomyometrium; E19 - right ovary with hemorrhagic corpus luteum cyst; E20 - right tube; E21 - left ovary; E22 - left tube with paratubal cyst. Jar 3.

### SYNOPTIC REPORTING FORM FOR UTERINE CERVICAL NEOPLASMS

#### HISTOPATHOLOGIC TYPE

Adenocarcinoma, not otherwise specified

#### TUMOR SIZE

The maximum depth of the tumor invasion is 0.6 cm

The breadth (maximum horizontal dimension) of the tumor is 3.3 cm

The total thickness of the cervix is 1.1 cm

#### LYMPHATIC INVASION

Lymphatic invasion by tumor is not identified

#### HISTOPATHOLOGIC GRADE

The histologic grade is poorly differentiated (G3)

#### TUMOR INVASION

The tumor does not invade through the entire thickness of the cervix to involve contiguous parametrial tissues.

#### VAGINAL INVOLVEMENT

The tumor does not involve the vagina

#### TUMOR METASTASIS

Metastasis of tumor to regional lymph nodes is absent

The total number of metastatically-involved lymph nodes is 0

The total number of lymph nodes examined is 10

Extracapsular extension of metastatic tumor through the lymph node capsule is not applicable; no metastasis seen

#### PRIMARY TUMOR (T)

Clinically visible lesion 4.0 cm or less in greatest dimension (T1b1/IB1)

Patient Name: [REDACTED]  
DOB: [REDACTED]

## Surgical Pathology Report

Final

### SURGICAL PATHOLOGY REPORT

#### REGIONAL LYMPH NODES

No regional lymph node metastasis (N0)

#### DISTANT METASTASIS

Can not be assessed (Mx)

#### STAGE GROUPING

The final stage of the tumor is pT1b1/N0/MX

The pathologic stage assigned here should be regarded as provisional, and may change after integration of clinical data not provided with this specimen.

#### Addenda/Procedures

Addendum Ordered:	Status: Signed Out
Addendum Complete:	By:
Addendum Signed Out:	

#### Addendum Comment

The endocervical adenocarcinoma tumor cells are diffusely positive for p16 by immunohistochemical stain.

#### Surgical Pathology report is available on-line on

The performance characteristics of some immunohistochemical stains, (immunoperoxidase, avidin-biotin-horseradish peroxidase, fluorescent antibody, and immunofluorescence), used in this report, if any, were determined by the U.S. Food and Drug Administration to be laboratory developed tests or Unapproved Clinical Laboratory Improvement Act of 1988 (CLIA '88) Tests. Some of these tests rely on the use of "highly specific reagents" and "reference reagents" which may only be performed in a facility that is certified by the Department of Health and Human Services as a high complexity laboratory under CLIA '88. The FDA has determined that such determinations or approvals do not apply to these tests as they are not intended for investigation or for research. Nevertheless, under rules concerning the availability of analytic specific reagents require that the testing laboratory be certified as a high complexity laboratory under CLIA '88. This test was developed and its performance characteristics determined by the Surgical Pathology Department of [REDACTED]. It has not been cleared or approved by the U.S. Food and Drug Administration.

END OF REPORT

Page 4 of 4